EFTA02351022.pdf

From: Misha Gromov Sent: Sunday, May 15, 2016 8:25 AM To: Jeffrey E. Subject: Re: 50/50 is generous; also will make me more involved if you ta=e it. the erson I s oke to is Victoria Nik=forova below is the (rather long) summary/advertisement she sent me=on my request We plan to bring to the healthcare marke= what we call a HealthSpan Pass — an individual rec=mmendation (an individually designed healthcare pathway) on molecular adju=tments for healthy ageing and healthspan extension, based on simultaneous =nalysis of near all molecules (comprising a human metabolome) in a microsa=ple of blood by metabolomics approach being imposed on our academic expert-se in molecular metabolism of ageing. In the production workflow we utilise bl=od metabolomics technology for identification of the molecular changes ass=ciated with ageing and biomarkers of age-related disorders. Current and pa=t medicinal interventions, individual lifestyle habits and dietary prefere=ces are also reflected in a molecular composition of blood as a universal =etabolic information integrator. From such analysis imposed on our know-wh= on human molecular metabolism, we are able to determine the impact of par=icular metabolites on the developmental trajectory of healthy agei=g, to diagnose pre- pathological healthspan violations and to indi=ate the precise molecular targets for personalised fine tuning of ageing metabolism. Additionally, to expand availability of our ser=ice and to make it distance-independent, we plan to develop a self=sampling device compatible with our technological metabolomics pl=tform, and to bring it to a medical self-care market as a valuable side pr=duct. In the developmental process of our main=product HealthSpan Pass, two more add-value side products will be created:=UniMetaMarker (universal metabolic biomarker panel) and c=trong>AgeMetaMarker (healthspan metabolic biomarker panel). A bio=arker panel is a set of molecules, selected from human metabolome, with in=icative diagnostic properties and a synergistic prognostic power (over an =ndividual biomarker molecule). Our biomarker panels will be utilised for d=ug discovery, with special emphasis on metabolic disorders. Being particul=rly targeted on drug discovery for age-associated diseasesatherosclerosis and cardiovascu=ar disease, cancer, arthritis, osteoporosis, type 2 diabetes, hypertension= Alzheimer's disease and Parkinson's disease, and further aim R&a=p;D at improved mechanisms of controlling and combating age-related chroni= and metabolic diseases through identification of novel drug targe=s among the involved molecules. We expect high demand for both bi=marker panels - the UniMetaMarker and the AgeMetaMarker - from pharma industry involved in drug development, and sp=cial interest to the AgeMetaMarker from those on ageing-r=lated market. Results of our research and development of the UniMetaMarker=and the AgeMetaMarker will be utilised in designing of our main product, t=e HealthSpan Pass - a personalised recommendation for fine tuning of metab=lism, based on detection of metabolic alterations critical for healthspan =n an individual metabolome. EFTA_R1_01329057 EFTA02351022 Global health policy disposition. </-pan>We are goin= to develop a product for individualised care, which does not exist yet on=the market, although there will definitely be a demand for it in line with=the Precision Medicine <https://www.nih.gov/precision-medicine-initiative-corort-program> Initiative of the National Institutes of Health (USA) a=d the Smart Care=/a> project (EU). Ac=ording to NIH, "Precision medicine is an emerging approach for disea=e treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person&rdquo=. The Smart Care Project piloted in the first ten EU regions also aims at =he individual care to be delivered to older European citi=ens, with special emphasis on combating threats to independent living and =n self-care support. World Health Organization (WHO) in its last year <http://www.pilotsmartcare.eu/home/> Metanomics Health G=bH <http://www.who.int/ageing/events/world-report-2015-launch/en/= target=> ), are =oncentrated mainly around large-scale analytics for pharma industry. As di=tinct from Metabolon, we from the very beginning aim our business at routi=izing diagnostic metabolomics for personalised health care, and go ahead b= offering a prognostic metabolomics product for individual health improvem=nt sharpened at ageing and healthspan extension. So, current market dispos=tion makes our product unique and targeted at near future of healthcare in=ustry. Being with our intended HealthSpan Pass =roduct a half-step ahead of the market, we plan fast busi=ess growth. Elaborated business development model implies attainment of pr=jected HealthSpan Pass production in a timeframe of 18 to 30 month= by the force of 10 to 14 business workers, depe=ding on raised financing. For a quick launch, we have ass=mbled a highly qualified start-up team with German academic (Max Planck So=iety) and industrial (BASF) biomedical innovation expertise. We plan parallel growth of our busine=s in four main infrastructure directions: Research & Development of biological markers; two biomark=r panels will be developed: UniMetaMarker (universal meta=olic biomarker panel as an add-value side product) and AgeMetaMark=r (healthspan metabolic biomarker panel) Technology development — most investment intens=ve (IP-reach, detailization provided by request), implies:=/p> - asse=bly of metabolite profiling machinery, and - tech=ical development of the device compatible with profiling machinery for sel= blood collection Business development (product support program provided by req=est) HealthSpan Pass — development of workflow & product=on With the HealthSpan Pass we dare to d=fine 'Healthy Ageing - Happy Living' as our mission. 2 EFTA_R1_01329058 EFTA02351023 On Fri, 13 May 2016 22:36:14 +0200, jeffrey E. wrote: 1. always , if i invest in somethi=g you bring to me. the deal is the same for all my friends. &nb=p; I put up all the money, take all the financial risk ,=and if there is a profit you and i split it 50/50. 2. I , wrestling with , meaning in a musical phrase. /&nbs=; notes with out a relationship to each other . &nb=p; is composition the arrow on the note category. . = can we tell if the string is melodic. does the information in=the string somehow give us a window.? repetition. relati=n. temporal. , absolute number bounds. ? &nbs=; max notes per sec? 3. in your meaning re shape same issue. when i= round , round. coarse grain? etc. it appears to m= that if something has meaning , that something is bounded. &nb=p; . please note The information contained in this communication is confidential, =ay be attorney-client privileged, may constitute inside information, =nd is intended only for the use of the addressee. It is the property =f TEE Unauthorized use, disclosure or copying of this commu=ication or any part thereof is strictly prohibited and may be unlawfu=. If you have received this communication in error, please notify us =mmediately by return e-mail or by e-mail to jeevacation@gmail.com <mailto:jeevaca=ion@gmail.com> , and destroy this communicat=on and all copies thereof, including all attachments. copyright -all =ights reserved 3 EFTA_R1_01329059 EFTA02351024